- Home
- BIPC vs TGTX Comparison
BIPC vs TGTX Comparison
Compare BIPC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIPC | TGTX |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | BIPC | TGTX |
|---|---|---|
| Price | $45.32 | $31.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $53.00 | $51.60 |
| AVG Volume (30 Days) | 532.9K | ★ 2.5M |
| Earning Date | 01-28-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $3,656,000,000.00 | $531,898,000.00 |
| Revenue This Year | $2.24 | $87.88 |
| Revenue Next Year | $5.63 | $47.78 |
| P/E Ratio | ★ N/A | $11.15 |
| Revenue Growth | 0.47 | ★ 100.88 |
| 52 Week Low | $32.08 | $25.28 |
| 52 Week High | $47.71 | $46.48 |
Technical Indicators
Market Signals| Indicator | BIPC | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 56.43 |
| Support Level | $44.08 | $29.80 |
| Resistance Level | $45.99 | $33.24 |
| Average True Range (ATR) | 1.00 | 1.64 |
| MACD | 0.06 | 0.28 |
| Stochastic Oscillator | 75.04 | 71.02 |
Price Performance
Historical ComparisonAbout BIPC Brookfield Infrastructure Corporation
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.